Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > OX40

OX40

Brief Information

Name:Tumor necrosis factor receptor superfamily member 4
Target Synonym:ATC35 Antigen,OX40 Antigen,ACT35,IMD16,OX40,Receptors, OX40,ACT35 antigen,TNFRSF4,CD134,TNF Receptor Superfamily Member 4,TAX Transcriptionally-Activated Glycoprotein 1 Receptor,CD134 Antigen,TXGP1L,Tumor Necrosis Factor Receptor Superfamily, Member 4,Lymphoid Activation Antigene ACT35,OX40 Homologue,Tumor necrosis factor receptor superfamily member 4,Tax-Transcriptionally Activated Glycoprotein 1 Receptor,OX40 Cell Surface Antigen,OX40L receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:26
Lastest Research Phase:Phase 3 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
OX40 mAb - 01 Lead AutoImmunity Autoimmune disease

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
EP-162 Human OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit
CHEK-ATP053 Human HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line
OX0-R52H8 Rabbit Rabbit OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-R52H8-structure
OX0-R52H8-sds
OX0-R52H9 Rat Rat OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-R52H9-structure
OX0-R52H9-sds
OX0-C82E9 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His,Avitag™
OX0-C82E9-structure
OX0-C82E9-sds
OX0-M82E5 Mouse Biotinylated Mouse OX40 / TNFRSF4 / CD134 Protein, His,Avitag™
OX0-M82E5-structure
OX0-M82E5-sds
OX0-H5252 Human Human OX40 / TNFRSF4 / CD134 Protein, Mouse IgG2a Fc Tag, low endotoxin
OX0-H5252-structure
OX0-H5252-sds
OX0-M522b Marmoset Marmoset OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-M522b-structure
OX0-M522b-sds
TN4-H82E4 Human Biotinylated Human OX40 / TNFRSF4 / CD134 Protein, Avitag™,His Tag (MALS verified) (recommended for biopanning)
TN4-H82E4-structure
TN4-H82E4-sds
OX0-R5253 Rat Rat OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-R5253-structure
OX0-R5253-sds
OX0-H82F7 Human Biotinylated Human OX40 Protein, Fc,Avitag™ (MALS verified)
OX0-H82F7-structure
OX0-H82F7-sds
OX0-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-C5251-structure
OX0-C5251-sds
OX0-C5220 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-C5220-structure
OX0-C5220-sds
OX0-M5259 Mouse Mouse OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-M5259-structure
OX0-M5259-sds
OX0-M5228 Mouse Mouse OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-M5228-structure
OX0-M5228-sds
OX0-H5224 Human Human OX40 / TNFRSF4 / CD134 Protein, His Tag (MALS verified)
OX0-H5224-structure
OX0-H5224-sds
OX0-H5255 Human Human OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-H5255-structure
OX0-H5255-sds
ACRO Quality

Synonym Name

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

Background

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rocatinlimab KHK-4083; AMG-451 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd, Amgen Inc Abdominal Pain; Digestive System Diseases; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Intestinal Diseases Details
Ivuxolimab PF-8600; PF-04518600 Phase 3 Clinical Pfizer Inc Solid tumours; Ovarian Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
INBRX-106 INBRX-106; ES-102; ES102 Phase 3 Clinical Inhibrx Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
GSK3174998 GSK3174998; GSK 3174998; GSK-3174998 Phase 2 Clinical Glaxosmithkline Plc Neoplasms; Multiple Myeloma Details
Telazorlimab GBR-830; ISB-830 Phase 2 Clinical Glenmark Pharmaceuticals Ltd Dermatitis, Atopic Details
BMS-986178 BMS-986178 Phase 2 Clinical Bristol-Myers Squibb Company Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
SAR-442970 SAR-442970 Phase 2 Clinical Sanofi Inflammation; Hidradenitis Suppurativa Details
IMG-007 IMG-007 Phase 2 Clinical Hutchmed (China) Ltd Alopecia Areata; Dermatitis, Atopic Details
BAT-6026 BAT-6026 Phase 2 Clinical Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd, Bio-Thera Solutions Ltd Solid tumours; Autoimmune Diseases; Dermatitis, Atopic Details
BGB-A445 BGB-A445 Phase 2 Clinical Beigene Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Recombinant human anti-OX40 monoclonal antibody (Livzon Group) Phase 1 Clinical Livzon Pharmaceutical Group Inc Neoplasms Details
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma Details
FS-120 FS-120 Phase 1 Clinical F-Star Neoplasms; Neoplasm Metastasis Details
Cudarolimab IBI-101 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
ATOR-1015 ADC-1015; ATOR-1015 Phase 1 Clinical Alligator Bioscience Ab Solid tumours; Neoplasms Details
Revdofilimab ABBV-368; PR-1628103 Phase 1 Clinical Abbvie Inc Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SHR-1806 SHR-1806 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd Neoplasms Details
Tavolimab MEDI-0562 Phase 1 Clinical Medimmune Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Melanoma Details
Vonlerolizumab RG-7888; MOXR-0916; RO-7021608 Phase 1 Clinical Genentech Inc Neoplasms; Carcinoma, Transitional Cell Details
EMB-09 EMB-09 Phase 1 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) YH-002 Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours Details
HFB-3010(HiFiBiO Therapeutics) HFB-3010; HFB-301001 Phase 1 Clinical HiFiBiO Therapeutics Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Sarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
HLX-51 HLX-51 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Lymphoma Details
KN-052 KN-052 Phase 1 Clinical Suzhou Alphamab Co Ltd Solid tumours Details
MEDI-6469 MEDI-6469; AGX-051 Phase 1 Clinical Providence Cancer Center, AgonOx Inc, Astrazeneca Plc, Providence Health & Services Liver Neoplasms; Head and Neck Neoplasms; Solid tumours; Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message